Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bristol-Myers Squibb Co. (NYSE: BMY).

Full DD Report for BMY

You must become a subscriber to view this report.


Recent News from (NYSE: BMY)

Ziopharm's Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think
Recently, Ziopharm Oncology (ZIOP) gave an update on its first-quarter 2018 earnings report. It noted that a phase 3 study would be paused for the time being . The biotech is now pointing to its other mid-stage studies as being more prominent than the phase 3 study that was supposed to st...
Source: SeekingAlpha
Date: May, 14 2018 03:55
Trump speech on drug prices light on specifics
Key points from President Trump's speech detailing his plan to lower U.S. drug prices called American Patients First: More news on: Health Care Select Sect SPDR ETF, Vanguard Health Care ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 14:25
Celldex Trying To Regroup With Its Early-Stage Assets
It was clear back in April that Celldex Therapeutics ( CLDX ) would be restructuring and realigning its priorities after the failure of its Phase III METRIC study of glembatumumab ("glemba") in triple-negative breast cancer, and after the first quarter earnings report, investors have a clear...
Source: SeekingAlpha
Date: May, 11 2018 11:59
Trump plan on drug prices to be announced this afternoon
President Trump is set to announce his plan to corral drug prices in a speech set to begin at 2:00 pm ET today. According to administration officials the plan will not include a call to Congress to allow Medicare to negotiate drug prices, a move currently prohibited under federal law. Mo...
Source: SeekingAlpha
Date: May, 11 2018 10:22
Bristol-Myers Squibb- A Pharma Favorite
The biotechnology and pharmaceutical stocks have seen some tough times of late, especially Editor’s Portfolio holding Bristol-Myers Squibb ( BMY ), suggests Chuck Carlson , dividend reinvestment specialist and editor of DRIP Investor . The stock is down 25% since mid-February an...
Source: MoneyShow.com
Date: May, 10 2018 01:00
Novo Nordisk: An Objective Analysis
In January 2017 I analyzed the major pharmaceuticals sector which resulted in a buy recommendation for Novo Nordisk. The analysis included a target price, which was hit in September. I looked at the company again in October and new financials led to a new valuation, and as it turned out, a n...
Source: SeekingAlpha
Date: May, 08 2018 10:48
Merck Wastes No Time Waiting For End Results, Files For Approval Immediately
Recently, Merck ( MRK ) unveiled that it had filed an sBLA based on a phase 3 study in front-line lung cancer patients. This quick filing could give the big pharma a lead in obtaining quicker approval for this indication. This is just another potential quick approval that could put Merck on ...
Source: SeekingAlpha
Date: May, 07 2018 20:41
The No BS Report, Week 12: Living In Yawnsville With Little But Gains
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an...
Source: SeekingAlpha
Date: May, 06 2018 08:58
Regeneron: Like Apple In 2016, Hated But Great - And Ready To Roll
Back story - The strong outperformance of large cap biotechs ( IBB ) and probably junior biotechs ( XBI ) from about 2010 to mid-2015 may be analogous to the run of "tech" from late 1994 to tech's mid-1998 peak: long, strong and somewhat overdone, but not a real bubble. And, set to rec...
Source: SeekingAlpha
Date: May, 04 2018 10:15
3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: May, 04 2018 08:00

 


About Bristol-Myers Squibb Co. (NYSE: BMY)

Logo for Bristol-Myers Squibb Co. (NYSE: BMY)

Not available

 

Contact Information

 

 

Current Management

  • Sandra Leung / Secretary

Current Share Structure

  • Market Cap: $84,767,164,432 - 05/11/2018
  • Issue and Outstanding: 1,634,538,458 - 03/31/2018

 


Recent Filings from (NYSE: BMY)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 22 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NYSE: BMY)

Daily Technical Chart for (NYSE: BMY)


Stay tuned for daily updates and more on (NYSE: BMY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: BMY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BMY and does not buy, sell, or trade any shares of BMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/